Genetic variation in NFE2L2 is associated with outcome following aneurysmal subarachnoid haemorrhage.

Publication

Genetic variation in NFE2L2 is associated with outcome following aneurysmal subarachnoid haemorrhage.

Journal Paper/Review - Oct 2, 2022

Gaastra Benjamin, Duncan Poppy, Bakker Mark K, Hostettler Isabel, Alg Varinder S, Houlden Henry, Ruigrok Ynte M, Galea Ian, Tapper Will, Werring David J, Bulters Diederik

Citation

Gaastra B, Duncan P, Bakker M, Hostettler I, Alg V, Houlden H, Ruigrok Y, Galea I, Tapper W, Werring D, Bulters D. Genetic variation in NFE2L2 is associated with outcome following aneurysmal subarachnoid haemorrhage. Eur J Neurol 2022; 30:116-124.

Type

Journal Paper/Review (English)

Journal

Eur J Neurol 2022; 30

Publication Date

Oct 2, 2022

Issn Electronic

1468-1331

Pages

116-124

Brief description/objective

Nuclear factor erythroid 2-related factor 2 (NRF2; encoded by the NFE2L2 gene) has been implicated in outcome following aneurysmal subarachnoid haemorrhage (aSAH) through its activity as a regulator of inflammation, oxidative injury and blood breakdown product clearance. The aim of this study was to identify whether genetic variation in NFE2L2 is associated with clinical outcome following aSAH.